The Business Times
business-time-50

Novo Nordisk

Companies & Markets

Ozempic-maker Novo Nordisk underwhelms investors with soft Wegovy pill sales

2026-08-06T00:00:47.000Z
A pharmaceutical firm in India has launched a weight-loss injection that costs from 1,290 rupees (S$17) a month.
Opinion & Features
THINKING ALOUD

A GLP-1 tsunami is headed for the vice industry. Good.

2026-05-25T23:15:00.000Z
India is the first major market to see a flood of copycat semaglutide medications.
Consumer & Healthcare

Low-cost Ozempic copies launch in India as Novo Nordisk’s patent expires

2026-03-22T08:41:20.000Z
The deals include agreements with Eli Lilly and Novo Nordisk to slash the prices of popular GLP-1 weight-loss drugs.
International

Trump unveils TrumpRx discounted drugs website

2026-02-06T02:02:20.000Z
Jay Thyagarajan, senior VP for Apac at Novo Nordisk, says that one way the company intends to manage patent expiries is through continued investments in R&D, including work on novel drug formulations.
Companies & Markets
TOPLINE

‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base

2026-01-25T23:00:00.000Z
Under a November deal with the Trump administration, Novo agreed to sell starter doses of their weight-loss pills if approved.
Consumer & Healthcare

Novo Nordisk shares jump almost 8% after US approves Wegovy pill

2025-12-23T13:03:24.000Z
Pop Mart, the Chinese firm behind Labubu dolls (above), is battling a scourge of fake Lafufus that have flooded online marketplaces.
Opinion & Features
PERSPECTIVE

What Novo Nordisk, OpenAI and Pop Mart have in common

2025-12-19T22:30:00.000Z
Novo chief executive officer Mike Doustdar has been pushing to rebuild momentum in the company’s pipeline following intense competition in the weight-loss drug market.
Companies & Markets

Novo gets 15 billion euros of orders for Akero acquisition bonds

2025-11-13T14:08:27.000Z
Pfizer said it would pay US$86.25 per share in cash, a premium of 3.69 per cent to Metsera’s Friday close.
Companies & Markets

Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle

2025-11-08T04:14:17.000Z
Novo Nordisk became Europe’s most valuable firm from rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow
International

Novo Nordisk lowers full-year profit guidance in new CEO’s maiden quarter

2025-11-05T10:18:16.000Z
Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More